The coronavirus disease 2019 (COVID-19) pandemic is causing worldwide uncertainty and anxiety. This unease is especially acute for those with the vague "underlying conditions" that render them more vulnerable to the infection or severe complications. People with rheumatic disease are likely to fall into this category because they are often immunocompromised as a result of their diseases and the medications used to treat them. Adding to this concern is the lack of explicit data for this population.

Rheumatological societies have been quick to offer reassurance in the form of broad guidelines on COVID-19. The European League Against Rheumatism (EULAR), among others, have [advised](https://www.eular.org/eular_guidance_for_patients_covid19_outbreak.cfm){#interrefs10} that patients remain on prescribed medication unless their physician says otherwise---a response to the temptation of patients to reduce or stop medications that compromise their immune system. Those who test positive for COVID-19, however, should temporarily discontinue certain treatments, according to [draft recommendations](https://www.rheumatology.org/Portals/0/Files/ACR-COVID-19-Clinical-Guidance-Summary-Patients-with-Rheumatic-Diseases.pdf){#interrefs20} released by the American College of Rheumatology (ACR). Face-to-face contact with a doctor is also discouraged in favour of remote contact whenever possible, as recommended by the [British Society for Rheumatologists (BSR)](https://www.rheumatology.org.uk/News-Policy/Details/Covid19-Coronavirus-update-members){#interrefs30}. The BSR also points out that, in the absence of data about specific vulnerabilities among patients with rheumatic disease, everyone should practice social distancing.

The [COVID-19 Global Rheumatology Alliance](https://rheum-covid.org/){#interrefs40} hopes to address the gap in data on patients with rheumatic diseases. Their new registry aims to collect information from medical practitioners worldwide on how COVID-19 interacts with rheumatic diseases and their associated comorbidities and medications, in an effort to best help patients through this challenging time. The Alliance encourages the reporting of all confirmed cases; they [report](https://doi.org/10.1016/S2665-9913(20)30095-3){#interrefs50} the preliminary characteristics of the first 110 individuals in the registry in the *Lancet Rheumatology*.

The evidence from this collaborative effort should allow rheumatologists to offer better-informed responses to their patients\' questions. Many of those questions revolve around patients seeing their prescribed drugs hyped in the news media as possible treatments for COVID-19. Indeed, in patients with severe COVID-19 and evidence of hyperinflammation, there is some evidence that immunosuppression might be [helpful](https://doi.org/10.1016/S0140-6736(20)30628-0){#interrefs60}. As such, several drugs used to treat rheumatic disease are being investigated in COVID-19 [clinical trials](https://doi.org/10.1016/S2665-9913(20)30089-8){#interrefs70}: the interleukin (IL)-1 receptor blocker anakinra, and the IL-6 pathway inhibitors tocilizumab and sarilumab to treat cytokine release syndrome; and the Janus Kinase (JAK) inhibitors tofacitinib and baricitinib to reduce inflammation and possibly also viral invasion of host cells. This has led to [speculation](https://doi.org/10.1016/S2665-9913(20)30092-8){#interrefs80} that patients with rheumatic diseases who already take these cytokine inhibitors might actually be protected against the most severe manifestations of disease.

But perhaps the greatest media hype has been around hydroxychloroquine---a drug commonly prescribed for rheumatoid arthritis and systemic lupus erythematosus (SLE). Preclinical data has shown that hydroxychloroquine exhibits anti-viral activity against [SARS-CoV-2 in vitro](https://doi.org/10.1038/s41422-020-0282-0){#interrefs90}. Several non-randomised trials have been reported for hydroxychloroquine, but none of these reach the usual standards expected for drug approval. Despite this, the US Food and drug administration (FDA) has granted its emergency approval for treatment of COVID-19, as has also been done in other countries. Whether these drugs will finally prove efficacious for COVID-19 is uncertain. What is certain, however, is that the decision has serious implications for those with rheumatic diseases who rely on these drugs to control their symptoms.

Even before the FDA approval, shortages of hydroxychloroquine were being reported. The ACR has warned that withdrawal of this drug from patients with SLE for as little as two weeks is likely to result in flares. They recommend that a stock of hydroxychloroquine be [earmarked](https://www.rheumatology.org/Portals/0/Files/Guiding-Principles-Scarce-Resource-Allocation-During-Covid-19.pdf){#interrefs100} for those with rheumatic diseases and outline safeguards to protect those most in need.

ACR, EULAR, and other rheumatological societies deserve recognition for their leadership and for advocating for the needs of patients with rheumatic diseases during the COVID-19 pandemic. Whether patients with rheumatic disease have worse (or better) outcomes with this disease is unknown for now, but the pandemic has highlighted the close collaboration of the rheumatology community who we trust will provide answers to this question soon.
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